Literature DB >> 24290245

Skin involvement in atypical hemolytic uremic syndrome.

Gianluigi Ardissino1, Francesca Tel2, Sara Testa2, Angelo Valerio Marzano3, Riccardo Lazzari3, Stefania Salardi2, Alberto Edefonti2.   

Abstract

Skin involvement in atypical hemolytic uremic syndrome (aHUS) is very uncommon and therefore often unrecognized as a specific symptom of aHUS. We describe 3 cases of patients with aHUS who developed skin lesions that completely recovered when disease-specific treatment was established. These cases suggest that in individuals with aHUS, when skin lesions of unknown origin occur, the possibility that they are due to thrombotic microangiopathy should be considered.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Haemolytic uremic syndrome; case report; eculizumab; plasma exchange; skin; thrombotic microangiopathy

Mesh：

Substances：

Year:  2013        PMID： 24290245     DOI： 10.1053/j.ajkd.2013.09.020

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


  13 in total

Review 1.  Current treatment of atypical hemolytic uremic syndrome.

Authors:  Bernard S Kaplan; Rebecca L Ruebner; Joann M Spinale; Lawrence Copelovitch
Journal:  Intractable Rare Dis Res       Date:  2014-05

Review 2.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

3.  Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Authors:  Arvind Bagga; Priyanka Khandelwal; Kirtisudha Mishra; Ranjeet Thergaonkar; Anil Vasudevan; Jyoti Sharma; Saroj Kumar Patnaik; Aditi Sinha; Sidharth Sethi; Pankaj Hari; Marie-Agnes Dragon-Durey
Journal:  Pediatr Nephrol       Date:  2019-04-15       Impact factor: 3.714

Review 4.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

Review 5.  Extra-renal manifestations of atypical hemolytic uremic syndrome.

Authors:  Cassandra Formeck; Agnieszka Swiatecka-Urban
Journal:  Pediatr Nephrol       Date:  2018-08-14       Impact factor: 3.714

6.  Cutaneous and renal glomerular vasculopathy as a cause of acute kidney injury in dogs in the UK.

Authors:  L P Holm; I Hawkins; C Robin; R J Newton; R Jepson; G Stanzani; L A McMahon; P Pesavento; T Carr; T Cogan; C G Couto; R Cianciolo; D J Walker
Journal:  Vet Rec       Date:  2015-03-23       Impact factor: 2.695

Review 7.  Extra-renal manifestations of complement-mediated thrombotic microangiopathies.

Authors:  Johannes Hofer; Alejandra Rosales; Caroline Fischer; Thomas Giner
Journal:  Front Pediatr       Date:  2014-09-08       Impact factor: 3.418

Review 8.  Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.

Authors:  Lilian M Pereira Palma; Craig B Langman
Journal:  J Blood Med       Date:  2016-04-12

9.  Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab.

Authors:  Gregory T Greenwood
Journal:  Int Med Case Rep J       Date:  2015-10-13

10.  The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.

Authors:  Jihad Ben Gabr; Hiba Bilal; Kanish Mirchia; Andras Perl
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.